172 related articles for article (PubMed ID: 36486181)
1. Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia A Canadian healthcare payer perspective.
Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
Can Urol Assoc J; 2023 Apr; 17(4):103-110. PubMed ID: 36486181
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):113-118. PubMed ID: 35689083
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore.
Chay J; Tung JYM; Su RJ; Aslim EJ; Wong C; Swan G; Chua WJ; Ho HSS; Finkelstein EA
J Med Econ; 2023; 26(1):1269-1277. PubMed ID: 37800562
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia.
Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Amorosi SL; Shore ND
J Health Econ Outcomes Res; 2021 May; 8(1):42-50. PubMed ID: 33987450
[No Abstract] [Full Text] [Related]
5. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Fu S; Bhattacharyya SK; El-Arabi AM; Cutone BJ; McVary KT
PLoS One; 2022; 17(4):e0266824. PubMed ID: 35427376
[TBL] [Abstract][Full Text] [Related]
6. Medium-Term Real-World Outcomes of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: Water Vapor Thermal Therapy (Rezum)
Chin CP; Garden EB; Ravivarapu KT; Shukla D; Omidele O; Levy M; Qian D; Araya JS; Valenzuela R; Reddy A; Marshall S; Motola J; Nobert C; Gupta M; Small AC; Kaplan SA; Palese MA
J Endourol; 2022 Dec; 36(12):1559-1566. PubMed ID: 36039926
[No Abstract] [Full Text] [Related]
7. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.
Cornu JN; Zantek P; Burtt G; Martin C; Martin A; Springate C; Chughtai B
Eur Urol; 2023 Jun; 83(6):534-547. PubMed ID: 36964042
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
Erman A; Masucci L; Krahn MD; Elterman DS
BJU Int; 2018 Nov; 122(5):879-888. PubMed ID: 30113127
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system.
Anezaki H; Endo F; Swan G; Takashima K; Rojanasarot S
J Med Econ; 2024; 27(1):554-565. PubMed ID: 38466193
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Private Payer and Patient Out-of-Pocket Costs Associated With the Surgical Management of Benign Prostatic Hyperplasia.
Wymer KM; Thao V; Narang G; Sharma V; Borah BJ; Cheney S; Humphreys MR
Urology; 2024 Feb; 184():87-93. PubMed ID: 38065310
[TBL] [Abstract][Full Text] [Related]
11. Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis.
Franco JVA; Jung JH; Imamura M; Borofsky M; Omar MI; Escobar Liquitay CM; Young S; Golzarian J; Veroniki AA; Garegnani L; Dahm P
BJU Int; 2022 Aug; 130(2):142-156. PubMed ID: 34820997
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of pharmacotherapy versus prostatic urethral lift as initial therapy for patients with moderate benign prostatic hyperplasia.
Tung JY; Aslim EJ; Ho HS; Chen C
Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):63-68. PubMed ID: 36342223
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia.
Wymer KM; Narang G; Slade A; Sharma V; Thao V; Borah BJ; Rivera M; Cheney S; Humphreys MR
Urology; 2023 Jan; 171():96-102. PubMed ID: 36270339
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system.
De la Cuadra-Grande A; Rioja-Zuazu J; Domínguez-Esteban M; Torres E; Blissett R; Woodward E; Oyagüez I; Fernández-Arjona M
Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):499-510. PubMed ID: 36897833
[TBL] [Abstract][Full Text] [Related]
15. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Jung JH; Reddy B; McCutcheon KA; Borofsky M; Narayan V; Kim MH; Dahm P
Cochrane Database Syst Rev; 2019 May; 5(5):CD012832. PubMed ID: 31128077
[TBL] [Abstract][Full Text] [Related]
16. Patients' Perspectives on Attributes While Choosing Minimally Invasive Surgery for Benign Prostatic Hyperplasia Procedures: Experience from Men Undergoing Water Vapor Thermal Therapy.
Rojanasarot S; Cutone B; Durand K; Zorn KC; Chughtai B; Bhojani N; Elterman DS
J Endourol; 2023 May; 37(5):575-580. PubMed ID: 36762936
[No Abstract] [Full Text] [Related]
17. New Endoscopic In-office Surgical Therapies for Benign Prostatic Hyperplasia: A Systematic Review.
Tzeng M; Basourakos SP; Lewicki PJ; Hu JC; Lee RK
Eur Urol Focus; 2022 Mar; 8(2):522-531. PubMed ID: 33663982
[TBL] [Abstract][Full Text] [Related]
18. Benign prostatic hyperplasia surgical re-treatment after prostatic urethral lift A narrative review.
Dean NS; Assmus MA; Lee MS; Guo JN; Krambeck AE
Can Urol Assoc J; 2023 Oct; 17(10):353-359. PubMed ID: 37494319
[TBL] [Abstract][Full Text] [Related]
19. Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.
Wei Y; Hay JW; Hay AR; Suen SC
BMC Urol; 2022 May; 22(1):76. PubMed ID: 35550071
[TBL] [Abstract][Full Text] [Related]
20. A novel metric for treatment durability in clinical trials of minimally invasive treatments for benign prostatic hyperplasia.
Miller LE; Te AE; Bhattacharyya SK; Lilienfeld S; Dornbier RA; McVary KT
Expert Rev Med Devices; 2020 Apr; 17(4):365-369. PubMed ID: 32189535
[No Abstract] [Full Text] [Related]
[Next] [New Search]
